Novo Nordisk Announces Significant Investment To Expand Its Montes Claros Brazil Manufacturing Site

Montes Claros – Novo Nordisk today announced an investment of R$6.4 billion (8 billion Danish kroner) to expand its production facility in Montes Claros, northern Minas Gerais, with the aim of increasing production capacity for injectable treatments for people with obesity, diabetes and other serious chronic diseases.

Marking one of the largest pharmaceutical investments in Brazil’s history, the expansion will significantly increase the facility’s capacity with the addition of new aseptic production processes, a warehouse and a new quality control laboratory. The facility will serve a variety of product formats, including GLP-1 products, and will feature advanced, future-proof technology.

“With this expansion of the Montes Claros site, we are strengthening our global production capacity, which will enable us to meet both current and future demand for innovative medicines worldwide,” said Henrik Wulff, Executive Vice President, Chemistry, Production, Control & Product Supply at Novo Nordisk.

Construction work has already begun and operations are expected to begin in 2028. The investment is expected to create 600 permanent jobs upon completion of the facility. During the construction phase, up to 2,000 external employees will work on site.

“This announcement is a historic milestone for Novo Nordisk in Brazil and highlights our unwavering commitment to innovation and excellence in the country as we continue to invest in this strategic manufacturing facility,” said Reinaldo Costa, corporate vice president of Novo Nordisk’s Montes Claros plant.

The facility will be designed with sustainability in mind and will pursue LEED certification. Low-carbon building materials will be used wherever possible, and 100% of the facility’s energy supply will come from solar photovoltaic (PV) panels. In addition, the facility will utilize innovative water management strategies, including rainwater harvesting and reuse for production.

About Novo Nordisk's factory in Brazil

The company has been present in Brazil since 1990 and currently has more than 2,000 employees. It is present in two states, with an administrative office in São Paulo (SP) and a production unit in Montes Claros (MG).

About Novo Nordisk production

Novo Nordisk has a global manufacturing footprint with strategic production sites located in Denmark, the United States, France, Brazil, China and Belgium. Novo Nordisk’s medicines are manufactured at these sites and then distributed to patients around the world. This includes the production of almost half of the world’s insulin, GLP-1 medicines for the treatment of diabetes and obesity, and medicines for the treatment of rare diseases such as hemophilia and growth disorders. Novo Nordisk’s manufacturing operations employ more than 30,000 people who are dedicated to delivering the highest quality to patients globally in an efficient and environmentally sustainable manner.

About Novo Nordisk

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, building on our heritage in fighting diabetes. We do this by pioneering scientific advances, expanding access to our medicines, and working to prevent and ultimately cure diseases. Novo Nordisk employs approximately 76,300 people in 80 countries and markets its products in approximately 170 countries. For more information, visit novonordisk.com , Facebook , Instagram , X , LinkedIn and YouTube